Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | CES1 | P23141 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.52 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27484553 | 0.91 | ALDH1A1 (0.53) | MAPK1CES1ALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL125002 | 0.86 | MAPK1 (0.60) | MAPK1CES1ALDH1A1CA1CA2 | |
| SCHEMBL5369565 | 0.83 | MAPK1 (0.51) | MAPK1CES1ALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL7103170 | 0.83 | MAPK1 (0.51) | MAPK1CES1ALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL11684646 | 0.82 | ALDH1A1 (0.59) | MAPK1CES1ALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL11684654 | 0.82 | CRHBP (0.58) | MAPK1CES1ALDH1A1CA1CA2 | |
| SCHEMBL5390211 | 0.82 | MAPK1 (0.55) | MAPK1CES1ALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL8002619 | 0.82 | MAPK1 (0.55) | MAPK1CES1ALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL11793491 | 0.82 | MAPK1 (0.55) | MAPK1CES1ALDH1A1SMN1; SMN2CA1 | |
| SCHEMBL27884533 | 0.82 | ALDH1A1 (0.57) | MAPK1CES1ALDH1A1SMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116903545-A | Synthesis method of formamide sulfosulfuron | 江苏省农用激素工程技术研究中心有限公司 | 2023-10-20 | — | — | CN | claimed |
| EP-4667054-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2025-12-24 | — | — | EP | disclosed |
| EP-3880660-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| CN-113166065-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-11-28 | — | — | US | disclosed |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| CN-118359548-A | Preparation method of benzodiazepine compound | 重庆医科大学 | 2024-07-19 | — | — | CN | disclosed |
| EP-4349820-A2 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | Novartis AG (CH) | 2024-04-10 | — | — | EP | disclosed |
| EP-3658539-B1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-111094242-B | Compounds and compositions for treating disorders associated with NLRP activity | 诺华股份有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-1582274-A | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade | WARNER LAMBERT CO (US) | 2005-02-16 | — | — | CN | disclosed |
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-01-13 | — | — | US | disclosed |
| US-6794395-B1 | Substituted indolinones, their manufacture and their use as medicaments | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-21 | — | — | US | disclosed |
| WO-2004026829-A2 | HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-04-01 | — | — | WO | disclosed |
| EP-0906279-B1 | PYRROLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-6136844-A | ANTIINFLAMMATORY AGENT; AUTOIMMUNE DISEASE | SYNTEX (U.S.A.) INC. (US) | 2000-10-24 | — | — | US | disclosed |
| US-6127402-A | AN INHIBITORS OF PROSTAGLANDIN G/H SYNTHASE AND ARE ANTI-INFLAMMATORY AND ANALGESIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 2000-10-03 | — | — | US | disclosed |
| US-5952368-A | AN INHIBITORS OF PROSTAGLANDIN G/H SYNTHASE, ANTIINFLAMMATORY AND ANALGESIC AGENTS | SYNTEX (U.S.A.) INC. (US) | 1999-09-14 | — | — | US | disclosed |
| EP-0906279-A1 | NOVEL PYRROLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-04-07 | — | — | EP | disclosed |
| WO-1997046524-A1 | NOVEL PYRROLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009898-A1 | New substituted indolinones, their manufacture and their use as medicaments | CCNE1, CDK1, CCNI | MAPK1 235/4885CES1 2442/4885ALDH1A1 1840/4885 |
| US-12084424-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | MAPK1 1647/4885CES1 820/4885ALDH1A1 1972/4885 |
| US-20240391884-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | NLRP1, NLRP3, NOD1 | MAPK1 1647/4885CES1 820/4885ALDH1A1 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.